Reshaping the gene therapy landscape
with AI-powered AAV vectors

The Outlook

Gene therapies of the future will be designed using artificial intelligence (AI) to reach more patients and treat many more diseases.

Our Solution

Dyno Therapeutics is applying AI technology to discover novel gene therapy vectors with transformative delivery properties for a vast landscape of human diseases.

OUR SCIENCE

Read about our scientists' publications in Science, Nature Biotechnology, at ASGCT and more.

SERIES A FINANCING

Dyno closes $100 million Series A financing led by Andreessen Horowitz

OUR PARTNERS

Astellas for AAV vectors directed to skeletal and cardical muscle

Roche for AAV vectors directed to CNS and liver

Sarepta for next-gen gene therapy vectors for muscle disease

Novartis for ocular collaboration to develop improved gene therapies

OUR LAB

Read about Dyno's cutting edge lab where high-throughput experiments power our search for transformative vectors.

XCONOMY AWARD

Dyno wins Xconomy's 2020
Startup of the Year award
Back to Top